An application for an Investigational New Drug (IND) for HBM7004, a novel B7H4xCD3 bispecific antibody designed to treat advanced solid tumors, has been accepted by China's National Medical Products Administration (NMPA).
This development follows the recent clearance of an IND application for HBM7004 by the U.S. Food and Drug Administration, as previously announced by the company on May 8, 2026, which authorized the initiation of a first-in-human Phase I clinical trial in the United States.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.